KETOCONAZOLE, AN ORAL ANTIFUNGAL - LABORATORY AND CLINICAL-ASSESSMENT OF IMIDAZOLE DRUGS
KETOCONAZOLE, AN ORAL ANTIFUNGAL - LABORATORY AND CLINICAL-ASSESSMENT OF IMIDAZOLE DRUGS
复制标题
DOI：
10.1136/pgmj.55.647.657
复制
发表时间：
1979-01-01
影响因子：
5.1
通讯作者：
STEVENS, DA
中科院分区：
文献类型：
--
作者：
BORELLI, D;FUENTES, J;STEVENS, DA
咪康唑是一种咪唑类抗真菌药，经肠道给药对人体全身真菌感染有疗效。酮康唑类似物可口服。在低浓度下对大多数真菌有抑制作用。动物和人经口给药后的血液水平大大超过这些抑制浓度数小时。该药物的疗效已在动物模型中得到证实。初步临床评价显示，16例可评价的全身和浅表真菌感染患者中有13例对200-400 mg/天的治疗产生了反应，涉及10种真菌病原体。迄今为止，在这些人体研究中未观察到毒性。酮康唑是一种有前途的药物，需要进一步广泛的评价。
Miconazole, a parenterally administered imidazole antifungal agent has been shown to produce responses in systemic fungal infections in man. Ketoconazole, an analogue, can be given by mouth. It is inhibitoryin vitroat low concentrations to most fungi. Blood levels after oral administration to animals and man greatly exceed these inhibitory concentrations for several hours. The efficacy of this drug has been demonstrated in animal models. Initial clinical evaluation has produced responses to therapy with 200–400 mg/day in 13 of 16 evaluable patients with systemic and superficial fungal infections, involving 10 fungal pathogens. No toxicity has been noted to date in these human studies. Ketoconazole is a promising agent needing further extensive evaluation.